trade name drug target s molecule type developer s owner fda approval Search Results


software solutions  (Biosym Technologies)
90
Biosym Technologies software solutions
Software Solutions, supplied by Biosym Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/software+solutions/10__1557_slash_s0883769400039312-142-40-0
Average 90 stars, based on 1 article reviews
software solutions - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
dna clean concentrator 5 kit  (Zymo Research)
99
Zymo Research dna clean concentrator 5 kit
Dna Clean Concentrator 5 Kit, supplied by Zymo Research, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/DNA+Clean+%26+Concentrator-5/bio_rxiv__2025__09__10__675267-172-15-20
Average 99 stars, based on 1 article reviews
dna clean concentrator 5 kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
bax system real-time e. coli o157:h7 single target pcr assay  (Qualicon Inc)
90
Qualicon Inc bax system real-time e. coli o157:h7 single target pcr assay
Bax System Real Time E. Coli O157:H7 Single Target Pcr Assay, supplied by Qualicon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/bax+pcr+system/10__4315_slash_0362___028x___82__sp1__1-11521-5-25
Average 90 stars, based on 1 article reviews
bax system real-time e. coli o157:h7 single target pcr assay - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mtorc1  (Selleck Chemicals)
94
Selleck Chemicals mtorc1
(A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the <t>mTORC1</t> inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.
Mtorc1, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/Temsirolimus/pmc05963255-235-36-39
Average 94 stars, based on 1 article reviews
mtorc1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
hpv vaccine  (Merck & Co)
86
Merck & Co hpv vaccine
(A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the <t>mTORC1</t> inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.
Hpv Vaccine, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/hpv+quadrivalent+vaccine/walhart_tara__2016__novel_inhibitors_of_the_human_papillomavirus-238-35-37
Average 86 stars, based on 1 article reviews
hpv vaccine - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
hcdc4/fbw7  (Koepp Schaum GmbH)
90
Koepp Schaum GmbH hcdc4/fbw7
(A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the <t>mTORC1</t> inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.
Hcdc4/Fbw7, supplied by Koepp Schaum GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/scffbxw7+hcdc4/pm17574027-34-2-11
Average 90 stars, based on 1 article reviews
hcdc4/fbw7 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
trbs07 antibody  (Trion Research)
90
Trion Research trbs07 antibody
(A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the <t>mTORC1</t> inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.
Trbs07 Antibody, supplied by Trion Research, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/trbs07+antibody/us10787519-902-60-64
Average 90 stars, based on 1 article reviews
trbs07 antibody - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
car t cells  (Novartis)
86
Novartis car t cells
(A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the <t>mTORC1</t> inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.
Car T Cells, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/car+cells+t/sec_filing____1652130_slash_000095017022001981_slash_ntla___20211231-347-12-3
Average 86 stars, based on 1 article reviews
car t cells - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
molecule drugs against certain rna targets  (Pfizer Inc)
86
Pfizer Inc molecule drugs against certain rna targets
(A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the <t>mTORC1</t> inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.
Molecule Drugs Against Certain Rna Targets, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/against+certain+drugs+molecule+rna+targets/sec_filing____911177_slash_000119312514251471_slash_d708462d10k-496-27-17
Average 86 stars, based on 1 article reviews
molecule drugs against certain rna targets - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
polyclonal antibody against target protein  (Danaher Inc)
99
Danaher Inc polyclonal antibody against target protein
(A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the <t>mTORC1</t> inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.
Polyclonal Antibody Against Target Protein, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/Goat+polyclonal+Anti-GST3+%2F+GST+pi+antibody/pmc08324298-294-5-17
Average 99 stars, based on 1 article reviews
polyclonal antibody against target protein - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
oseltamivir  (Gilead Sciences)
97
Gilead Sciences oseltamivir
(A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the <t>mTORC1</t> inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.
Oseltamivir, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/Tamiflu/pmc07020694-183-14-15
Average 97 stars, based on 1 article reviews
oseltamivir - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
pcr targets  (Qiagen)
97
Qiagen pcr targets
(A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the <t>mTORC1</t> inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.
Pcr Targets, supplied by Qiagen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/Reverse+transcriptase/pmc04948299-25-52-41
Average 97 stars, based on 1 article reviews
pcr targets - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier

Image Search Results


(A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the mTORC1 inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.

Journal: Cell reports

Article Title: Deletion of the imprinted gene, Grb10, promotes hematopoietic stem cell self-renewal and regeneration

doi: 10.1016/j.celrep.2016.10.025

Figure Lengend Snippet: (A) At left, representative flow cytometric plots are shown of BrdU+ donor CD45.2+ BM cells at 48 hours following transplantation of BM cells from Grb10 +/+ mice or Grb10 m/+ mice into CD45.1+ recipients. At right, the scatter plot shows the mean percentage of BrdU+ BM cells in each group (n=6/group). (B) Mean percentages of Grb10 +/+ and Grb10 m/+ KSL cells in G0, G1 and G2/S/M phase at 3 hours after 300 cGy in vitro irradiation (n = 6/group). (C) Mean percentages of Annexin V+ cells in BM KSL cells from Grb10 +/+ and Grb10 m/+ mice, at 3 hours after 300 cGy in vitro irradiation (n = 8/group). (D) Mean numbers of CFCs from 500 BM KSL cells isolated from Grb10 +/+ and Grb10 m/+ mice at day +3 following 300 cGy in vitro (n = 6/group). (E) Expression of cyclin dependent kinases and cyclin proteins in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice at 3 hours after 300 cGy (n = 6/group). (F) Mean percentages of senescence associated-β-galactosidase (SA-β-Gal) positive CD34-KSL cells in Grb10 +/+ and Grb10 m/+ mice at 24h following 700cGy TBI (n = 8/group). (G) At left, representative flow cytometric analysis of SLAM+KSL cells in Grb10 +/+ mice and Grb10 m/+ mice at day +10 following 550 cGy TBI and treatment with and without the mTORC1 inhibitor, CCI-779. At right, scatter plot shows the numbers of BM SLAM+KSL cells in Grb10 +/+ and Grb10 m/+ mice at day + 10 following 550 cGy TBI and treatment with and without CCI-779 or MK2206, an Akt inhibitor (n = 6/group). (H) Mean ratios of CFC numbers from BM KSL cells in response to SCF treatment or no SCF treatment for 3 days, showing enhanced response in BM KSL cells from Grb10 m/+ mice (n = 6/group). (I) At left, representative fluorescence microscopic images (63x, scale bar=10μm) show the binding of Grb10 and c-kit proteins via proximity ligation assay in BM KSL cells from Grb10 +/+ mice and Grb10 m/+ mice following 15 min of SCF treatment. Blue = DAPI; red = Grb10 - c-kit complex; at right, scatter plot shows the mean fluorescence signal intensity of BM KSL cells in each group (n = 21-30, t test)(all panels, means ± SEM). See also Figure S2 and Figure S3.

Article Snippet: Senescent cells were stained for senescence activated β-galactosidase using the Quantitative Cellular Senescence Assay Kit (Cell Biolabs) and analyzed on a BD CANTO II (BD Biosciences). mTOR and Akt inhibition studies For in vivo inhibition of mTORC1, temsirolimus (CCI-779, Selleckchem) was reconstituted in ethanol at 10mg/ml and then diluted in 5% Tween-80 (Sigma-Aldrich) and 5% PEG (polyethylene glycol) 400 (Hampton Research).

Techniques: Transplantation Assay, In Vitro, Irradiation, Isolation, Expressing, Fluorescence, Binding Assay, Proximity Ligation Assay